Xorel-AX Capsule SR is a combination pharmaceutical formulation containing Aceclofenac 200 mg and Rabeprazole 20 mg, designed for sustained release to provide effective management of inflammatory conditions accompanied by gastric acid-related symptoms. Aceclofenac, a non-steroidal anti-inflammatory drug (NSAID), exerts potent analgesic and anti-inflammatory effects by selectively inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis responsible for pain and inflammation. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, thus protecting the gastric mucosa from NSAID-induced irritation and ulceration. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance and symptom control. Xorel-AX is indicated for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and other musculoskeletal disorders where inflammation and pain coexist with a risk of NSAID-induced gastrointestinal complications. It should be used under medical supervision, considering contraindications such as hypersensitivity to components, active peptic ulcer, or severe hepatic impairment. Monitoring for adverse effects including gastrointestinal discomfort, renal function alterations, and hypersensitivity reactions is recommended. The combination therapy in Xorel-AX Capsule SR offers a balanced approach to managing pain and inflammation while minimizing gastrointestinal risks associated with long-term NSAID use.